FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTORNEY DOCKET NO.: F7649(V)

SERIAL NO.: 10/519,657

FILING DATE: December 22, 2004

CONFIRMATION NO.: 9203

Page 1 of 1

| | | APPLICANT | | CONFIRMATIO | | | Page 1 of 1 | |
|---|---|---|-----------------------------|----------------------------------|----------------------------|--------------|---------------------------------|--|
| | | | U.S. P | ATENT DOCUMENTS | | | | |
| EXAMINER INITIALS | | DOCUMENT NO. | DATE | NAME OF INVENTOR | CLASS | SUBCLASS | FILING DATE IF APPROPRIAT | |
| | 1 | 5,821,217 | 10/13/98 | Forse et al. | 514 | 2 | | |
| | 2 | 2002/0019334 | 02/14/02 | Portman | 514 | 2 | | |
| | 3 | 2002/037830 | 03/28/02 | Berthelsen et al. | 514 | 2 | | |
| | 4 | 2005/0238694 | 10/27/05 | Gerhardt et al. | 424 | 439 | | |
| | | | FOREIGN | PATENT DOCUMENTS | | | | |
| EXAMINER INITIALS | | DOCUMENT NO. | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION YES OR NO | |
| | 5 | 629 350 | 12/21/94 | Europe | | | | |
| | 6 | 1 112 693 | 07/04/01 | Europe | | | | |
| | 7 | 01/85984 | 11/15/01 | PCT | | | | |
| | 8 | 2004/002241 | 01/08/04 | PCT | | | | |
| | 9 | 2 489 942 | 01/08/04 | Canada | | | | |
| | | | ОТН | IER DOCUMENTS | | | | |
| | 10 | Drucker, " <u>Development of Glucagon-Like Peptide-1-Based Pharmaceuticals as Therapeutic Agents for the Treatment of Diabetes</u> ", Current Pharmaceutical Design, 2001, 7, pgs. 1399-1412. | | | | | | |
| | 11 | Zander et al., "Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and ß-c function in type 2 diabetes: a parallel-group study", the Lancet, Vol. 359, 3/9/02, pgs. 824-830. | | | | | | |
| | Toft-Nielsen, " <u>Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes</u> ", J. Clinical Endocrin Metab 2001, 8/86(8): 3853-60. | | | | | | | |
| | 13 | Sensi et al., "Chronobiological Aspects of Weight Loss in Obesity: Effects of Different Meal Timing Regimens", Chronobiology International, Vol. 4, No. 2, 1987, pp. 251-261. | | | | | | |
| | 14 | Harper, "Biological Properties of Whey Components A Review", The American Dairy Products Institute, 2001, p. | | | | | | |
| 15 Harper, "Biological Properties of Whey Components A Review", The American Dairy Products | | | | | | | 2004, pgs. 1-44 | |
| | 16 | Nuttal et al., "Effect of Protein Ingestion on the Glucose and Insulin Response to a Standarized Oral Glucose Load", Diabetes Care, Vol. 7, No. 5, September-October 1984, pgs. 465-470. | | | | | | |
| | 17 Abubakar et al., "Structural Analysis of New Antihypertensive Peptides Derived from Cheese Whey Protein by K Digestion", J. Dairy Science, Vol. 81, No. 12, 1998, pgs. 3131-3138 | | | | | | | |
| | 18 | Co-pending Application Attorney Docket No.: F | n: Applicant: Ge 7683(V) | rhardt et al., Serial No. 10/539 | ,434; Filed: Janua | ry 13, 2006; | | |
| XAMINER /Jeffrey Russel/ | | | | DATEC | DATE CONSIDERED 03/24/2009 | | | |